Zacks Research Downgrades Takeda Pharmaceutical (NYSE:TAK) to Strong Sell

Takeda Pharmaceutical (NYSE:TAK) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other brokerages have also weighed in on TAK. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Weiss Ratings cut Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, June 23rd. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical currently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $16.02 on Monday. The company has a market capitalization of $50.97 billion, a price-to-earnings ratio of 41.07 and a beta of -0.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.60 and a current ratio of 1.09. The company has a 50-day simple moving average of $16.13 and a 200 day simple moving average of $16.83. Takeda Pharmaceutical has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 4.31% and a return on equity of 11.20%. The firm had revenue of $6.90 billion for the quarter. On average, sell-side analysts predict that Takeda Pharmaceutical will post 0.94 earnings per share for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors increased its stake in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock worth $210,259,000 after acquiring an additional 82,643 shares during the period. UBS Group AG lifted its position in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after acquiring an additional 1,869,323 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in shares of Takeda Pharmaceutical by 100.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after acquiring an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.